Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Saskia M. Brachmann, Claudio Bomio-Confaglia et al.|Cancer Discovery|2022Cited by 134
Cancer lineage-specific regulation of YAP responsive elements revealed through large-scale functional epigenomic screensInês Amorim Monteiro Barbosa, Giorgio Giacomo Galli, Rajaraman Gopalakrishnan et al.|Nature Communications|2023Cited by 21